Déjàvu all over Again: Adverse Reactions to Nonnucleoside Reverse Transcriptase Inhibitors

Gallo RC . A personal perspective on HIV—AIDS research. J Hum Virol 1999;2:8–18.

Johnson SC Gerber JG . Advances in HIV/AIDS therapy. Adv Intern Med 2000;45:1–40.

Goodkin K . Deterring the progression of HIV infection. Compr Ther 1990;16:17–23.

Ho DD Neuman AU Perelson AS Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123–6.

Gazzard B . The picture of future therapy. Int J Clin Pract Suppl 1999;103:45–8.

Weinshilboum R . The therapeutic revolution. Clin Pharmacol Ther 1987;42:481–4.

van der Ven AJ Koopmans PP Vree TB van der Meer JW . Adverse reactions to cotrimoxazole in HIV infection. Lancet 1991;338:431–3.

Hess DA Rieder MJ . The role of reactive drug metabolites in immune-mediated adverse drug reactions. Ann Pharmacother 1997;31:1378–87.

Carr A Samaras K Burton S Law M Freund J Chisholm DJ A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;7:51–8.

Bonfanti P Capetti A Riva P Testa L Quirino T . Hypersensitivity reactions during antiretroviral regimens with protease inhibitors. AIDS 1997;11:1301–2.

Moyle GJ Gazzard BG . A risk—benefit analysis of HIV protease inhibitors. Drug Saf 1999;20:299–321.

Gangar M Arias G O'Brien JG Kemper CA . The frequency of cutaneous reactions complicating the initial use and rechallenge with nevirapine and delavirdine. Ann Pharmacother 2000;34:839–42.

Reichman RC Morse GD Demeter LM Resnick L Bassiakos Y Fischl M Phase I study of ateviradine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type I infection. J Infect Dis 1995;171:297–304.

Bossi P Colin D Bricaire F Caumes E . Hypersensitivity syndrome associated with efavirenz therapy. Clin Infect Dis 2000;30:227–8.

Adkins JC Noble S . Efavirenz. Drugs 1998;56:1055–64.

Musoke P Guay LA Bagenda D Mirochnick M Nadabiito C Fleming T A Phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1 infected pregnant Ugandian women and their neonates (HIVNET 006). AIDS 1999;11:479–86.

Pollard RB Robinson P Dransfield K . Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998;20:1071–92.

Warren KJ Boxwell DE Kim NY Drolet BA . Nevirapine-associated Stevens—Johnson syndrome (letter). Lancet 1998;351:567.

Bourezane Y Salard D Hoen B Vandel S Drobacheff C Laurent R . DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis 1998;27:1321–2.

Anton P Soriano V Jimenez-Nacher I Rodriguez-Rosado R Dona MC Barrerior PM Incidence of rash and discontinuation of nevirapine using two different escalating doses. AIDS 1999;13:524–5.

Rieder MJ Matsui D . Adverse drug reactions in paediatrics: A rationale approach. In: Koren G Diav-Citrin O , eds. Paediatric pharmacology — towards evidence-based drug therapy. Baillière's Clinical Paediatrics. Vol. 6. No 3. London: Baillières Tindell, 1998:505–19.

Grant DM . Pharmacogenetics and the changing face of clinical pharmacology. Can J Clin Pharmacol 1999;6:131–2.

Klein M . AIDS and HIV vaccines. Vaccine 1999;(17 S2):S65–70.

Romerio F Gallo RC . Novel biologic approaches for the treatment of AIDS. J Lab Clin Med 1999;134:577–84.